Abstract
The benefits of multi-target action are well established in a variety of pathological models. Many dietary supplements and nutraceuticals may be useful to slow age-related cognitive declines and the risk of developing neurodegenerative disease. L-Carnosine and EGCG are natural compounds that have received particular attention because of their potential role in modulating oxidative stress associated with aging and chronic conditions. The biological activities of these naturally occurring substances have frequently been used to prevent or reduce senile features; however they have never been evaluated as a combined treatment. In the present study we investigated the combined effect of L-Carnosine and EGCG on the activation of two stress-responsive pathways: HO-1 and Hsp72 (the inducible form of Hsp70), which play an important role in cytoprotection against oxidative stress-induced cell damage. We demonstrated that the neuroprotective effects of EGCG and L-Carnosine are achieved through the modulation of HO-1/Hsp72 systems. Furthermore, the combined action of both compounds resulted in a synergistic increase of HO-1 expression which suggests a crosstalk between the HO-1 and the Hsp72-mediated pathways. Our results indicate that the combined administration of EGCG and L-Carnosine would benefit the treatment and prevention of neurodegenerative diseases by reducing the neuronal damage caused by oxidative stress.
Keywords: Oxidative stress, synergy, nutraceuticals, antioxidants, heme oxygenase-1, heat shock protein, aging, neuroprotection
Current Pharmaceutical Design
Title:Synergistic Effect of L-Carnosine and EGCG in the Prevention of Physiological Brain Aging
Volume: 19 Issue: 15
Author(s): Sergio Davinelli, Roberto Di Marco, Renata Bracale, Alessandro Quattrone, Davide Zella and Giovanni Scapagnini
Affiliation:
Keywords: Oxidative stress, synergy, nutraceuticals, antioxidants, heme oxygenase-1, heat shock protein, aging, neuroprotection
Abstract: The benefits of multi-target action are well established in a variety of pathological models. Many dietary supplements and nutraceuticals may be useful to slow age-related cognitive declines and the risk of developing neurodegenerative disease. L-Carnosine and EGCG are natural compounds that have received particular attention because of their potential role in modulating oxidative stress associated with aging and chronic conditions. The biological activities of these naturally occurring substances have frequently been used to prevent or reduce senile features; however they have never been evaluated as a combined treatment. In the present study we investigated the combined effect of L-Carnosine and EGCG on the activation of two stress-responsive pathways: HO-1 and Hsp72 (the inducible form of Hsp70), which play an important role in cytoprotection against oxidative stress-induced cell damage. We demonstrated that the neuroprotective effects of EGCG and L-Carnosine are achieved through the modulation of HO-1/Hsp72 systems. Furthermore, the combined action of both compounds resulted in a synergistic increase of HO-1 expression which suggests a crosstalk between the HO-1 and the Hsp72-mediated pathways. Our results indicate that the combined administration of EGCG and L-Carnosine would benefit the treatment and prevention of neurodegenerative diseases by reducing the neuronal damage caused by oxidative stress.
Export Options
About this article
Cite this article as:
Davinelli Sergio, Di Marco Roberto, Bracale Renata, Quattrone Alessandro, Zella Davide and Scapagnini Giovanni, Synergistic Effect of L-Carnosine and EGCG in the Prevention of Physiological Brain Aging, Current Pharmaceutical Design 2013; 19 (15) . https://dx.doi.org/10.2174/1381612811319150007
DOI https://dx.doi.org/10.2174/1381612811319150007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies
Current Neuropharmacology Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Hyperhomocysteinemia, Pteridines and Oxidative Stress
Current Drug Metabolism Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer,s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Current Alzheimer Research Increased Alzheimer’s Disease Neuropathology is Associated with Type 2 Diabetes and ApoE ε4 Carrier Status
Current Alzheimer Research Relevance of Mutations in Tau for Understanding the Tauopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds
Current Pharmaceutical Design Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Current Pharmaceutical Design Status Epilepticus: An Overview
Current Drug Metabolism Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study
Current Alzheimer Research The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome
Current Diabetes Reviews Selective Neuronal Nitric Oxide Synthase Inhibitors
Current Topics in Medicinal Chemistry Novel Hybrid Anticonvulsants Derived from Pyrrolidine-2,5-dione Scaffold with Broad Spectrum of Activity in the Preclinical Studies
Current Topics in Medicinal Chemistry Aβ Metallobiology and the Development of Novel Metal-Protein Attenuating Compounds (MPACs) for Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimer’s Disease Patients vs. Drug Treated Parkinson’s Disease Patients vs. Age-matched Normal Controls
Current Alzheimer Research Actigraphy for Assessing Light Effects on Sleep and Circadian Activity Rhythm in Alzheimer's Dementia: A Narrative Review
Current Alzheimer Research Imaging of Sigma1 Receptors in the Human Brain Using PET and [11C]SA4503
Central Nervous System Agents in Medicinal Chemistry Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism